BSE
IPCALAB

IPCA LABORATORIES LTD.

Drug Manufacturers-Specialty & Generic
Healthcare

Prices are adjusted according to historical splits.

IPCA LABORATORIES LTD. Stock Price

Vitals

Today's Low:
₹886.75
Today's High:
₹912.95
Open Price:
₹894.1
52W Low:
₹670
52W High:
₹1028.7404
Prev. Close:
₹898.9
Volume:
8153

Company Statistics

Market Cap.:
₹206.63 billion
Book Value:
230.269
Revenue TTM:
₹62.48 billion
Operating Margin TTM:
11.26%
Gross Profit TTM:
₹40.63 billion
Profit Margin:
7.54%
Return on Assets TTM:
5.41%
Return on Equity TTM:
8.36%

Company Profile

IPCA LABORATORIES LTD. had its IPO on under the ticker symbol IPCALAB.

The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. IPCA LABORATORIES LTD. has a staff strength of 16,167 employees.

Stock update

Shares of IPCA LABORATORIES LTD. opened at ₹894.1 at the start of the last trading session i.e. 2023-09-13.

The stocks traded within a range of ₹886.75 - ₹912.95, and closed at ₹896.55.

This is a -0.26% slip from the previous day's closing price.

A total volume of 8,153 shares were traded at the close of the day’s session.

In the last one week, shares of IPCA LABORATORIES LTD. have increased by +1.81%.

IPCA LABORATORIES LTD.'s Key Ratios

IPCA LABORATORIES LTD. has a market cap of ₹206.63 billion, indicating a price to book ratio of 3.7935 and a price to sales ratio of 3.7514.

In the last 12-months IPCA LABORATORIES LTD.’s revenue was ₹62.48 billion with a gross profit of ₹40.63 billion and an EBITDA of ₹9.46 billion. The EBITDA ratio measures IPCA LABORATORIES LTD.'s overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, IPCA LABORATORIES LTD.’s operating margin was 11.26% while its return on assets stood at 5.41% with a return of equity of 8.36%.

In Q1, IPCA LABORATORIES LTD.’s quarterly earnings growth was a negative -41.1% while revenue growth was a positive 17.5%.

IPCA LABORATORIES LTD.’s PE and PEG Ratio

Forward PE
0
Trailing PE
43.8348
PEG

Its diluted EPS in the last 12-months stands at ₹18.58 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into IPCA LABORATORIES LTD.’s profitability.

IPCA LABORATORIES LTD. stock is trading at a EV to sales ratio of 3.6275 and a EV to EBITDA ratio of 18.5539. Its price to sales ratio in the trailing 12-months stood at 3.7514.

IPCA LABORATORIES LTD. stock pays annual dividends of ₹4 per share, indicating a yield of 0.5% and a payout ratio of 21.53%.

Balance sheet and cash flow metrics

Total Assets
₹86.26 billion
Total Liabilities
₹18.06 billion
Operating Cash Flow
₹-7250000000.00
Capital Expenditure
₹4.94 billion
Dividend Payout Ratio
21.53%

IPCA LABORATORIES LTD. ended 2024 with ₹86.26 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹86.26 billion while shareholder equity stood at ₹58.42 billion.

IPCA LABORATORIES LTD. ended 2024 with ₹0 in deferred long-term liabilities, ₹18.06 billion in other current liabilities, 253700000.00 in common stock, ₹58.17 billion in retained earnings and ₹381.40 million in goodwill. Its cash balance stood at ₹12.58 billion and cash and short-term investments were ₹22.75 billion. The company’s total short-term debt was ₹0 while long-term debt stood at ₹6.52 billion.

IPCA LABORATORIES LTD.’s total current assets stands at ₹51.89 billion while long-term investments were ₹0 and short-term investments were ₹4.22 billion. Its net receivables were ₹9.89 billion compared to accounts payable of ₹5.25 billion and inventory worth ₹17.43 billion.

In 2024, IPCA LABORATORIES LTD.'s operating cash flow was ₹-7250000000.00 while its capital expenditure stood at ₹4.94 billion.

Comparatively, IPCA LABORATORIES LTD. paid ₹0.22 in dividends in 2024.

Other key metrics

Current Trading Price
₹896.55
52-Week High
₹1028.7404
52-Week Low
₹670
Analyst Target Price

IPCA LABORATORIES LTD. stock is currently trading at ₹896.55 per share. It touched a 52-week high of ₹1028.7404 and a 52-week low of ₹1028.7404. Analysts tracking the stock have a 12-month average target price of .

Its 50-day moving average was ₹850.62 and 200-day moving average was ₹811.48 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 4666.3% of the company’s stock are held by insiders while 4068.2% are held by institutions.

Frequently Asked Questions About IPCA LABORATORIES LTD.

The stock symbol (also called stock or share ticker) of IPCA LABORATORIES LTD. is IPCALAB

The IPO of IPCA LABORATORIES LTD. took place on

Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)

Last Price
Chg
Chg%
₹142.5
-14.55
-9.26%
₹405.38
-0.79
-0.19%
₹143.33
2.53
+1.8%
₹0
0
0%
₹0.12
-0.01
-7.03%
₹1.58
-0.07
-4.24%
METCL (METCL)
₹25.45
-0.07
-0.25%
₹19.29
-0.16
-0.82%
₹119.1
-2.65
-2.18%
Applied Opt (AAOI)
₹11.36
-0.29
-2.49%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
₹0.14
0.07
+100%
₹0.12
0.04
+45.29%
₹0.96
0.05
+5.4%
₹1.34
-0.35
-20.71%
Humbl Inc (HMBL)
₹0
0
0%

Top Gainers

Last Price
Chg
Chg%
₹0
0
+172200%
₹0
0
+51200%
₹283
280.03
+9428.62%
₹11.2
10.57
+1667.68%
Latch Inc (LTCHW)
₹0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
₹0.19
-123.15
-99.85%
₹0
-0.11
-99.55%
₹0
-0
-97.96%
₹0
-0.01
-93.94%
₹0.01
-0.06
-92.24%

About

Ipca Laboratories Limited, a pharmaceutical company, manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India. It offers APIs in therapeutic areas of anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic. The company provides generic and branded formulations in the therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, diabetology, dermatology, gastroenterology, hematology, neurology, ophthalmology, rheumatology, and urology, as well as psychiatry, probiotics, respiratory, orthopedics, oral anti diabetes drug, nutraceuticals, NSAIDs, neuropathic pain, malaria, infectious diseases, immunosuppressant, hepatoprotectives, helminthics, fever, and emollients/protectives. It also exports its products worldwide. The company was incorporated in 1949 and is based in Mumbai, India.

Address

125, Kandivli Industrial Estate, Mumbai, India, 400067